{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:27:17Z","timestamp":1793953637808,"version":"4.8.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["MSCA-IF-EF-ST #894990"],"award-info":[{"award-number":["MSCA-IF-EF-ST #894990"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/01564"],"award-info":[{"award-number":["PI21\/01564"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.rmed.2026.108815","type":"journal-article","created":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T16:31:57Z","timestamp":1776011517000},"page":"108815","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Biological therapy for chronic obstructive pulmonary disease (COPD): Effectiveness and safety"],"prefix":"10.1016","volume":"256","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9921-883X","authenticated-orcid":false,"given":"Olga Milena","family":"Garc\u00eda Morales","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadna","family":"Auladell-Rispau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Poloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luz Angela","family":"Torres-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard Urr\u00fatia","family":"Cuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Ximena","family":"Rojas-Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2026.108815_bib1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease."},{"key":"10.1016\/j.rmed.2026.108815_bib2","unstructured":"The global economic burden of chronic obstructive pulmonary disease for 204 countries and territories in 2020-50: a health-augmented macroeconomic modelling study - PubMed, https:\/\/pubmed-ncbi-nlm-nih-gov.ezproxy.uniandes.edu.co\/37474226\/(accessed 15 March 2026)."},{"key":"10.1016\/j.rmed.2026.108815_bib3","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1164\/ajrccm.154.4.8887592","article-title":"Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (study to understand prognoses and preferences for outcomes and risks of treatments)","volume":"154","author":"Connors","year":"1996","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2026.108815_bib4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.rmed.2018.02.015","article-title":"Long term survival after admission for COPD exacerbation: a comparison with the general population","volume":"137","author":"van Hirtum","year":"2018","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2026.108815_bib5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2147\/COPD.S152291","article-title":"Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease","volume":"13","author":"Tashkin","year":"2018","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.rmed.2026.108815_bib6","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1136\/thoraxjnl-2020-215167","article-title":"Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait","volume":"76","author":"David","year":"2021","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2026.108815_bib7","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1164\/rccm.201104-0597OC","article-title":"Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers","volume":"184","author":"Bafadhel","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2026.108815_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e09736","article-title":"A systematic review and integrated analysis of biologics that target type 2 inflammation to treat COPD with increased peripheral blood eosinophils","volume":"8","author":"Ohnishi","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.rmed.2026.108815_bib9","first-page":"CD013432","article-title":"Anti-IL-5 therapies for chronic obstructive pulmonary disease","volume":"12","author":"Donovan","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.rmed.2026.108815_bib10","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1056\/NEJMoa2401304","article-title":"Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation","volume":"390","author":"Bhatt","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2026.108815_bib11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2303951","article-title":"Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts","volume":"389","author":"Bhatt","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2026.108815_bib12","volume":"vol 2025","author":"Morales","year":"2025"},{"key":"10.1016\/j.rmed.2026.108815_bib13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jclinepi.2022.09.020","article-title":"Methods for developing and reporting living evidence synthesis","volume":"152","author":"Bendersky","year":"2022","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.rmed.2026.108815_bib14","doi-asserted-by":"crossref","first-page":"192","DOI":"10.12688\/f1000research.51723.3","article-title":"Tailored PRISMA 2020 flow diagrams for living systematic reviews: a methodological survey and a proposal","volume":"10","author":"Kahale","year":"2021","journal-title":"F1000Research"},{"key":"10.1016\/j.rmed.2026.108815_bib15","unstructured":"Epistemonikos Foundation (n.d.). Living overview of evidence platform. L.OVE. https:\/\/iloveevidence.com\/index.htmlEpistemonikosFoundation.Epistemonikosdatabasemethods.Epistemonikos."},{"key":"10.1016\/j.rmed.2026.108815_bib16","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Br. Med. J."},{"key":"10.1016\/j.rmed.2026.108815_bib17","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"Br. Med. J."},{"key":"10.1016\/j.rmed.2026.108815_bib18","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S2213-2600(21)00556-7","article-title":"Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial","volume":"10","author":"Yousuf","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmed.2026.108815_bib19","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","article-title":"Mepolizumab for eosinophilic chronic obstructive pulmonary disease","volume":"377","author":"Pavord","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2026.108815_bib20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12931-017-0633-7","article-title":"A randomised, placebo-controlled trial of anti-interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease","volume":"18","author":"Calverley","year":"2017","journal-title":"Respir. Res."},{"key":"10.1016\/j.rmed.2026.108815_bib21","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S2213-2600(21)00167-3","article-title":"Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial","volume":"9","author":"Rabe","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmed.2026.108815_bib22","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1905248","article-title":"Benralizumab for the prevention of COPD exacerbations","volume":"381","author":"Criner","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2026.108815_bib23","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S2213-2600(14)70187-0","article-title":"Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study","volume":"2","author":"Brightling","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmed.2026.108815_bib24","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1056\/NEJMoa2413181","article-title":"Mepolizumab to prevent exacerbations of COPD with an eosinophilic phenotype","volume":"392","author":"Sciurba","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2026.108815_bib25","article-title":"A phase III open-label extension study to evaluate the long-term safety of astegolimab in patients with chronic obstructive pulmonary disease","year":"2026","journal-title":"Clinic. Trial Reg. NCT05878769, clinicaltrials.gov"},{"key":"10.1016\/j.rmed.2026.108815_bib26","article-title":"A phase IIb, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of astegolimab in patients with chronic obstructive pulmonary disease","year":"2026","journal-title":"Clinic. Trial Reg. NCT05037929, clinicaltrials.gov"},{"key":"10.1016\/j.rmed.2026.108815_bib27","year":"2026","journal-title":"Clinic. Trial Reg. NCT05158387, clinicaltrials.gov"},{"key":"10.1016\/j.rmed.2026.108815_bib28","year":"2026","journal-title":"Clinic. Trial Reg. NCT05166889, clinicaltrials.gov"},{"key":"10.1016\/j.rmed.2026.108815_bib29","article-title":"Randomized, double-blind, placebo-controlled, parallel group phase 3 study to evaluate the efficacy, safety, and tolerability of SAR440340\/REGN3500\/Itepekimab (Anti-IL-33 mAb) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD)","author":"Sanofi","year":"2025","journal-title":"Clinic. Trial Reg. NCT04701983, clinicaltrials.gov"},{"key":"10.1016\/j.rmed.2026.108815_bib30","article-title":"Randomized, double-blind, placebo-controlled, parallel-group phase 3 study to evaluate the efficacy, safety, and tolerability of SAR440340\/REGN3500\/itepekimab (Anti-IL-33 mAb) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD)","author":"Sanofi","year":"2025","journal-title":"Clinic.Trial Reg. NCT04751487, clinicaltrials.gov"},{"key":"10.1016\/j.rmed.2026.108815_bib32","article-title":"A double-blinded extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies","year":"2025","journal-title":"Clinic. Trial Reg. NCT06208306, clinicaltrials.gov"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126001836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126001836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:02:06Z","timestamp":1793952126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611126001836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":31,"alternative-id":["S0954611126001836"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2026.108815","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biological therapy for chronic obstructive pulmonary disease (COPD): Effectiveness and safety","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2026.108815","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108815"}}